<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
<head>
    <meta charset="utf-8">
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <meta name="description" content="">
    <meta name="viewport" content="width=device-width, initial-scale=1">

    <title>Learn the Truth - Bracco</title>
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
	<link type="text/css" rel="stylesheet" href="http://fonts.googleapis.com/css?family=Dosis:400,200,300,500,600,700,800" media="all" />
    <link rel="stylesheet" href="css/custom.css">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js"></script>
      <script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
    <![endif]-->
</head>


<body>


<!-- ****************************** MODALS ****************************** -->
                                
    <!-- Case Study 1 Modal -->
    <div class="modal fade" id="CaseStudy1Modal" tabindex="-1" role="dialog" aria-labelledby="CaseStudy1Modal" aria-hidden="true">
      <div class="modal-dialog">
        <div class="modal-content">
          <div class="modal-body">
           <img src="img/casestudy1_large.jpg">
          </div>
        </div>
      </div>
    </div>


    <!-- Case Study 2 Modal -->
    <div class="modal fade" id="CaseStudy2Modal" tabindex="-1" role="dialog" aria-labelledby="CaseStudy2Modal" aria-hidden="true">
      <div class="modal-dialog">
        <div class="modal-content">
          <div class="modal-body">
           <img src="img/casestudy2_large.jpg">
          </div>
        </div>
      </div>
    </div>


<!-- ****************************** NAVIGATION ****************************** -->


    <nav class="navbar navbar-inverse" role="navigation">
      <div class="container nav__container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="sr-only">Toggle navigation</span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="http://imaging.bracco.com/us-en"><img src="img/bracco-logo.gif" alt="Bracco logo"></a>
          <a class="navbar__brand--mobile" href="http://imaging.bracco.com/us-en"><img src="img/bracco-logo-mobile.gif" alt="Bracco logo"></a>
        </div><!-- /.navbar-header -->
        
        <div class="navbar-collapse collapse">
			<ul>
                <li class="corporate first"><a href="http://corporate.bracco.com/gb-en">Corporate</a></li>
                <li class="diagnosis active"><a href="http://imaging.bracco.com/gb-en">Diagnosis &amp; Intervention</a></li>
                <li class="farmacia"><a href="http://farma.bracco.com/pre-home">Bracco pharma</a></li>
                <li class="servizi"><a href="http://salute.bracco.com/pre-home">Health services</a></li>
                <li class="pressroom"><a href="http://corporate.bracco.com/gb-en/press-room">Press Room</a></li>
                 <li class="contati"><a href="http://corporate.bracco.com/gb-en/local-contacts">Contacts</a></li>
            </ul> 
        </div><!--/.navbar-collapse .collapse -->
                    
        <div class="navemptyrow"></div>
        
      </div><!-- /.container -->
    </nav><!-- /.navbar .navbar-inverse -->


<!-- ****************************** HEADER ****************************** -->


    <header>
    	<img src="img/headerimg.jpg" alt="Learn the Truth - Prohance (gadoteridol) vs. Gadavist (gadobutrol)">
    </header>


<!-- ****************************** MAIN CONTENT ****************************** -->

    
	<div class="container maincontent">


<!-- ****************************** SECTION 1 - Get the Whole Story ****************************** -->


            <section class="col-md-12 section1">
                <h1 class="bluetext">Get the <strong>WHOLE</strong> Story About CNS MR Contrast</h1>
                
                <hr class="hr-purple">
                
                <h2>The phase IV, double-blind, multi-center, randomized crossover study reveals there&rsquo;s more to the <strong class="strongpurple">TRUTH</strong> when comparing the clinical benefits of ProHance<sup>&reg;</sup> (gadoteridol) and Gadavist<sup>&reg;</sup> (gadobutrol):</h2>
                
                	<div class="container">
                        <div class="row">
                            <div class="col-md-8 list">
                                <ul>
                                    <li><span>ProHance and Gadavist produce <strong>no diagnostic differences</strong>.<sup>1, 2</sup></span></li>
                                    
                                    <li><span>The 2-fold higher concentration of Gadavist provides <strong>no benefits</strong> for routine morphologic imaging.<sup>1, 2</sup></span></li>
                                    
                                    <li><span>Gadavist <strong>does not demonstrate</strong> the clinical benefits for diagnostic performance associated with high relaxivity in CNS MRI.<sup>1-3</sup></span></li>
                                    
                                    <li><span>That means <strong>only MultiHance</strong><sup>&reg;</sup> (gadobenate dimeglumine) offers the highest relaxivity in CNS MRI to improve visualization of brain lesions.<sup>3-7</sup></span></li>
                                </ul>
                            </div><!-- /.col-md-8 -->
                            
                            <div class="col-md-4 logos">
                                <a href="http://imaging.bracco.com/us-en/products-and-solutions/magnetic-resonance-imaging/prohance"><img src="img/prohance-logo.png" alt="ProHance logo" class="prohancelogo"></a>
                                <span class="mobilebr"><br /></span>
                                
                                <a href="http://imaging.bracco.com/us-en/products-and-solutions/magnetic-resonance-imaging/multihance"><img src="img/multihance-logo.png" alt="MultiHance logo"></a>                               
                            </div><!-- /.col-md-4 -->
                        
                        </div><!-- /.row -->
                    </div><!-- /.container -->
                    
			<div class="scrollarrow"><img src="img/scrolldown.png"></div>
            
            </section><!-- /.col-md-12 section1 -->
    
        
<!-- ****************************** SECTION 2 - Case Studies ****************************** -->


            <section class="col-md-12 section2">
                <h1>Case Studies</h1>
                
                <hr class="hr-yellow">
                
                <h2>The TRUTH study results demonstrate no differences in contrast enhancement of lesion morphology.<sup>1</sup></h2>
                
                
                <div class="casestudies__btns">
                    <div class="casestudy__btn casestudy__btn--active" data-content="#CaseStudy1"><span>Case Study 1</span></div>
                    <div class="casestudy__btn" data-content="#CaseStudy2"><span>Case Study 2</span></div>
                </div><!-- /.casestudies__btns-->
                    
                 <div class="col-md-12 casestudies__boxes">    
                    <div class="row">
                    
                        <div id="CaseStudy1">                            
                            <div class="col-md-4 casestudy__text">
                                <p>61-year-old male with brain metastases from primary lung cancer. Two lesions clearly seen in both exams show no differences in contrast enhancement or in the morphology of lesions.<sup>1</sup></p>
                            </div><!-- /.col-md-4 .casestudy__text -->
                            
                            <div class="col-md-8 casestudy__img">
                                <a class="casestudyimg__modal" data-toggle="modal" data-target="#CaseStudy1Modal"><img src="img/casestudy1.jpg" alt="Case Study 1"></a>
                                <img src="img/casestudy1.jpg" alt="Case Study 1" class="casestudyimg--mobile">
                            </div><!-- /.col-md-8 .casestudy__img -->
                        
                        </div><!-- #CaseStudy1 -->
                    
                    
                        <div id="CaseStudy2" class="content">
                            <div class="col-md-4 casestudy__text">
                                <p>51-year-old female with glioblastoma multiforme. Rim-enhancing mass in right thalamus with extension into the posterior interhemispheric region is clearly seen in both examinations. No differences in contrast enhancement or in the morphology of lesions are apparent.<sup>1</sup></p>
                            </div><!-- /.col-md-4 .casestudy__text -->
                            
                            <div class="col-md-8 casestudy__img">
                                <a class="casestudyimg__modal" data-toggle="modal" data-target="#CaseStudy2Modal"><img src="img/casestudy2.jpg" alt="Case Study 2"></a>
                                <img src="img/casestudy2.jpg" alt="Case Study 2" class="casestudyimg--mobile">
                            </div><!-- /.col-md-8 .casestudy__img -->
                        </div><!-- #CaseStudy2 -->
                        
                    </div><!-- /.row -->
                 </div><!-- /.casestudies__boxes -->

                 
				<p class="reference"><small>These are representational images from reference studies. Individual results may vary. REFERENCE: 1. Maravilla K, Smith M, Vymazal J, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (The TRUTH study). <em>AJNR Am J Neuroradiol</em>. 2015;1:14-23, doi: 10.3174/ajnr.A4154.</small></p>
                
                <div class="scrollarrow"><img src="img/scrolldown.png"></div>
                
			</section><!-- /.col-md-12 section2 -->
    

<!-- ****************************** SECTION 3 - The 95% confidence intervals ****************************** -->


			<section class="col-md-12 section3">
                <h1 class="bluetext">The 95% confidence intervals for all qualitative assessments confirm that <strong>ProHance is not inferior to Gadavist.<sup>1</sup></strong></h1>
                
                <hr class="hr-purple">
                                
                <div class="col-md-5 chartstext">
                    <h2><strong>No significant differences</strong> noted by any reader for any parameter:<sup>1</sup></h2>
                    
                    <ul class="chartslist">
                        <li class="chartslist__item chartslist__item--active" data-target="#Charts" data-slide-to="0"><span>Global Diagnostic Preference</span></li>
                        <li class="chartslist__item" data-target="#Charts" data-slide-to="1"><span>Lesion Border Delineation</span></li>
                        <li class="chartslist__item" data-target="#Charts" data-slide-to="2"><span>Lesion Internal Morphology</span></li>
                        <li class="chartslist__item" data-target="#Charts" data-slide-to="3"><span>Lesion Qualitative Contrast Enhancement</span></li>
                        <li class="chartslist__item" data-target="#Charts" data-slide-to="4"><span>Lesion Extent</span></li>
                    </ul>            
                                        
                </div><!-- /.col-md-5 .chartstext -->
                

                <div id="Charts" class="col-md-7 carousel slide" data-ride="carousel">
                    <ol class="carousel-indicators">
                        <li data-target="#Charts" data-slide-to="0" class="active"></li>
                        <li data-target="#Charts" data-slide-to="1"></li>
                        <li data-target="#Charts" data-slide-to="2"></li>
                        <li data-target="#Charts" data-slide-to="3"></li>
                        <li data-target="#Charts" data-slide-to="4" ></li>
                    </ol>
            
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            <img src="img/chart1.png" alt="Global Diagnostic Preference bar graph">  
                        </div><!-- /.item.active -->
                        
                        <div class="item">
                            <img src="img/chart2.png" alt="Lesian Border Delineation bar graph">
                        </div><!-- /.item -->
                        
                        <div class="item">
                            <img src="img/chart3.png" alt="Lesion Internal Morphology bar graph">
                        </div><!-- /.item -->
                        
                        <div class="item">
                            <img src="img/chart4.png" alt="Lesion Qualitative Contrast Enhancement bar graph">
                        </div><!-- /.item -->
                        
                        <div class="item">
                            <img src="img/chart5.png" alt="Lesion Extent bar graph">
                        </div><!-- /.item -->
                    </div><!-- /.carousel-inner -->
                    
            	</div><!-- /#Charts .col-md-7 .carousel .slide -->            
            
            <div class="scrollarrow"><img src="img/scrolldown.png"></div>
            
            </section><!-- /.col-md-12 section3 -->
            
            
<!-- ****************************** SECTION 4 - The TRUTH Speaks for Itself ****************************** -->


            <section class="col-md-12 section4">
                <div class="container">
                    <div class="row">
                    	<div class="col-md-8 truthtext">
                            <h1>The <strong>TRUTH</strong> Speaks for Itself</h1>
                            
                            <hr class="hr-yellow">
                            
                            <p class="h1">Discover the advantage that ProHance and Bracco&rsquo;s suite of MR products can bring to your practice. </p>
                            
                            <p class="visitus">Visit our <a href="http://imaging.bracco.com/us-en" target="_blank">website</a> or <a href="http://imaging.bracco.com/us-en/bracco-rep" target="_blank">contact your rep</a> today.</p>
                        </div><!-- /.col-md-  -->
                        
                        <div class="col-md-4 truthbutton">
                        	<a href="http://www.ncbi.nlm.nih.gov/pubmed/25300984" target="_blank"><img src="img/abstractbutton.png" alt="Download the TRUTH Study Abstract"></a>
                        </div><!-- /.col-md-4  -->                                         
                        
                    </div><!-- /.row -->
                </div><!-- /.container -->

			</section><!-- /.col-md-12 section4 -->
            
            
<!-- ****************************** SECTION 5 - References ****************************** -->

    
        <div class="col-md-12 section5">
        
            <p class="reference"><small>REFERENCES: 1. Maravilla K, Smith M, Vymazal J, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (The TRUTH study). <em>AJNR Am J Neuroradiol</em>. 2015;1:14-23, doi: 10.3174/ajnr.A4154.  2. Gadavist (gadobutrol) injection, full Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2014.  3. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT study). <em>AJNR</em>. 2012;33(6):1050-1058.  4. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.  5. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5 and 3 Tesla. <em>Erratum Invest Radiol</em>. 2006;41:213-221.  6. Rowley HA, Scialfa G, Gao RY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. <em>AJNR</em>. 2008;29:1684-1691.  7. Maravilla KR, Maldijan JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. <em>Radiology</em>. 2006;240(2):389-400.</small></p>  
            
            <hr class="hr-blue">

        </div><!-- /.section5 -->
        
        
<!-- ****************************** ISI ****************************** -->    

			<div id="SafetyPreview">
            <!--<div id="SafetyPreview" style="position:static">-->
                <div class="container">
                    <p><strong>INDICATIONS AND USAGE FOR PROHANCE</strong><br />
                    <strong>Central Nervous System</strong><br />
                    ProHance (Gadoteridol) Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine, and associated tissues.</p>
                    <p><strong>Extracranial/Extraspinal Tissues</strong><br />
                    ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.</p>
                    <p class="safetyinfo__title">IMPORTANT SAFETY INFORMATION</p>
                </div><!-- /.container -->
            </div><!-- /#SafetyPreview -->

    
<!-- ****************************** SECTION 6 - Safety Information ****************************** -->

        <div class="col-md-12 section6">

			<p><strong>INDICATIONS AND USAGE FOR PROHANCE</strong><br />
            
            <strong>Central Nervous System</strong><br />
            
            ProHance (Gadoteridol) Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine, and associated tissues.</p>
            
            <p><strong>Extracranial/Extraspinal Tissues</strong><br />
            ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.</p>
            
            <p class="safetyinfo__title">IMPORTANT SAFETY INFORMATION</p>
    
    
            <div class="warningbox">
            
                <p class="text-center"><strong>WARNING: NEPHROGENIC SYSTEMIC FIBROSIS</strong></p>
                
                <p>Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.</p>
                
                <ul>
                    <li>The risk for NSF appears highest among patients with:
                        <ul>
                            <li>Chronic, severe kidney disease (GFR &lt;30 mL/min/1.73m<sup>2</sup>), or</li>
                            <li>Acute kidney injury.</li>
                        </ul></li>
                        
                    <li>Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.</li>
                    
                    <li>For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration <strong>[See WARNINGS].</strong></li>
                </ul>
                
            </div><!-- /.warningbox -->
            
            <p>As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes and renal insufficiency with or without hepatic imapairment. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.</p>
            
            <p>Please consult full <a href="http://imaging.bracco.com/us-en/products-and-solutions/magnetic-resonance-imaging/prohance/prescribing-information" target="_blank">Prescribing Information for ProHance</a> including boxed <strong>WARNING</strong> contained within this website.</p>
            <br />
            
            <p><strong>INDICATIONS AND USAGE FOR MULTIHANCE</strong><br />
            MultiHance is a gadolinium-based contrast agent indicated for use in:</p>
        
            <ul>
                <li>Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues and</li>
                
                <li>Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.</li>
            </ul>
            
            
            <p class="safetyinfo__title">IMPORTANT SAFETY INFORMATION</p>
            
            <div class="warningbox">
            
                <p class="text-center"><strong>WARNING: NEPHROGENIC SYSTEMIC FIBROSIS</strong></p>
                
                <p>Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.</p>
                
                <ul>
                    <li>The risk for NSF appears highest among patients with:
                        <ul>
                            <li>Chronic, severe kidney disease (GFR &lt;30 mL/min/1.73m<sup>2</sup>), or</li>
                            <li>Acute kidney injury.</li>
                        </ul>
                    </li>
                    
                    <li>Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.</li>
                    
                    <li>For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration. <strong>[See Warnings and Precautions <em>(5.1)</em>]<sup>&dagger;</sup>.</strong></li>
                </ul>
                
            </div><!-- /.warningbox -->
            
            
            <p>Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.</p>
            
            <p><sup>&dagger;</sup>Please consult full <a href="http://imaging.bracco.com/us-en/products-and-solutions/magnetic-resonance-imaging/multihance" target="_blank">Prescribing Information for MultiHance</a> including boxed <strong>WARNING</strong> contained within this website.</p>
            
            <p><strong>You are encouraged to report negative side effects of prescription drugs to the FDA.<br /> 
            Visit <a href="http://www.fda.gov/medwatch/" target="_blank">www.fda.gov/medwatch</a> or call 1-800-FDA-1088.</strong>
            
            <p>ProHance<sup>&reg;</sup> is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH &mdash; 78224 Singen (Germany).<br />
            MultiHance<sup>&reg;</sup> is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH &mdash; 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.</p>
            
            <p>All trademarks and registered trademarks are the property of their respective owners.</p>
            
            <p>Copyright &copy; 2015 Bracco Diagnostics Inc.<br />
            
            <span class="privacy-links">
                <a href="http://imaging.bracco.com/us-en/privacy-policy">Privacy Policy</a>
                <span class="vertical-divider">|</span><span class="privacy-links-br"><br /></span>
                <a href="http://imaging.bracco.com/us-en/terms-use">Terms of Use</a><span class="vertical-divider">|</span><span class="privacy-links-br"><br /></span>
                <a href="http://imaging.bracco.com/us-en/imprint">Imprint</a><span class="vertical-divider">|</span><span class="privacy-links-br"><br /></span>
            </span><!-- /.privacy-links -->
            
            <strong>THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY</strong></p>

        </div><!-- /.section6 -->



<!-- ****************************** FOOTER ****************************** -->

        <footer class="col-md-12">
        
        	<hr class="hr-blue hr-footer">
            
            <div class="row">
            
                <div class="col-md-10 footer__slogan">
                    <img src="img/bracco-slogan.gif" alt="Committed to Science, Committed to You.">
                </div><!-- /.col-md-10 -->
                
                <div class="col-md-2 footer__logo">
                    <a class="footer__logo--dt" href="http://imaging.bracco.com/us-en"><img src="img/bracco-logo.gif" alt="Bracco logo"></a>
                    <a class="footer__logo--mobile" href="http://imaging.bracco.com/us-en"><img src="img/bracco-logo-mobile.gif" alt="Bracco logo"></a>
                </div><!-- /.col-md-2 -->                
                
            </div><!-- /.row -->
        </footer>
        
        <div class="col-md-12 footer__bottom"></div>
        
	</div><!-- /.container .maincontent -->


    
	<script src="http://code.jquery.com/jquery-1.11.2.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
    <script src="js/custom.js"></script>



    
</body>
</html>
  